目的 探討?zhàn)B心定悸膠囊聯(lián)合多巴絲肼片對帕金森病患者的臨床療效。方法 選擇定州市人民醫(yī)院2017年8月-2019年8月收治的帕金森病患者60例作為研究對象，采用隨機原則將患者分為觀察組與對照組，每組各30例。對照組采用多巴絲肼片治療，初始劑量0.25 g/次，3次/d，1周后逐漸根據(jù)病情調(diào)整用量，直到達到適合患者的治療量為止，最高劑量不超過1 g/d，分3~4次服用。觀察組在對照組治療的基礎(chǔ)上聯(lián)合養(yǎng)心定悸膠囊，3 g/次，2次/d。兩組治療時間均為12周。觀察兩組患者的臨床療效，同時比較兩組治療前后的帕金森評定量表（UPDRS）、自主神經(jīng)癥狀量表（SCOPT-AUT）、帕金森生活質(zhì)量問卷（PDQ-39）評分及神經(jīng)遞質(zhì)水平。結(jié)果 治療后，觀察組患者總有效率90.00%，顯著高于對照組66.67%（P<0.05）。治療后，兩組UPDRS、SCOPT-AUT、PDQ-39評分均顯著降低，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療后，觀察組各評分顯著低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組血清血清5-羥色胺（5-HT）、去甲腎上腺素（NE）、多巴胺（DA）水平比較顯著升高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療后，觀察組5-HT、NE、DA水平顯著高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 養(yǎng)心定悸膠囊聯(lián)合多巴絲肼片治療帕金森病效果顯著，能夠顯著緩解癥狀，改善自主神經(jīng)功能和神經(jīng)遞質(zhì)水平，有利于患者生活質(zhì)量的提高，且具有較好的安全性。

Objective To investigate the effect of Yangxin Dingji Capsules combined with Levodopa and Benserazide Hydrochloride Tablets on patients with Parkinson's disease. Methods Patients (60 cases) with Parkinson's disease in Dingzhou City People's Hospital from August 2017 to August 2019 were selected as the study objects, and were randomly divided into observation group and control group, with 30 cases in each group. The control group was treated with Levodopa and Benserazide Hydrochloride Tablets, the initial dose was 0.25 g/time, three times daily, and the dosage was gradually adjusted according to the condition after 1 week, until the appropriate amount of treatment was reached, the maximum dose did not exceed 1 g/d for 3-4 times. The observation group was treated with Yangxin Dingji Capsules on the basis of control group, 3 g/time, twice daily. Both groups were treated for 12 weeks. The clinical efficacy of two groups was observed, and the scores of UPDRS, SCOPT-AUT, PDQ-39, and neurotransmitter levels before and after treatment were compared. Results After treatment, the total effective rate of the observation group was 90.00%, which was higher than 66.67% of the control group (P<0.05). After treatment, the scores of UPDRS, SCOPTAUT, and PDQ-39 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, these scores in the observation group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the serum levels of 5-HT, NE, and DA in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the levels of 5-HT, NE, and DA in the observation were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Yangxin Dingji Capsules combined with Levodopa and Benserazide Hydrochloride Tablets has a remarkable effect on the treatment of Parkinson's disease, which can significantly relieve symptoms, improve autonomic nerve function and neurotransmitter level, and is conducive to the improvement of patients' quality of life, and has a good safety.

R971

河北省中醫(yī)藥管理局科研課題（2020604）